Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100

Eli Lilly and Company (LLY) EV/FCF

Alert me on EV/FCF

As of 9 October 2026, Eli Lilly and Company (LLY) trades at a EV/FCF of 53.9×. Over the past ten years it has ranged from 16.2× (February 2018) to 534× (June 2024); the current reading is higher than 70% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 89.5× (26.10%)
FY2024 121× (45.88%)
FY2023 224× 277.89%
FY2022 59.2× 45.26%
FY2021 40.8× 35.42%
FY2020 30.1× (6.35%)
FY2019 32.1× 25.74%
FY2018 25.6× 38.98%
FY2017 18.4× (2.79%)
FY2016 18.9× (51.17%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 54.7× (10.57%)
Mar 2026 61.2× (31.58%)
Dec 2025 89.5× 42.35%
Sep 2025 62.8× (39.52%)
42 more quarters

Against its own ten years

Low 16.2× High 534×
Ten-year median 36.3×
Current reading's percentile 67

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on LLY